Natixis’s Pfizer PFE Stock Holding History

Natixis’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-103	Closed	-$5K	–	1152
2022 Q2	$5K	Buy	+103	New	+$5.25K	﹤0.01%	1099

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Natixis's PFE Position: Q2 2026 in Review

Natixis reduced its Pfizer (PFE) stake by 67% in Q2 2026, selling an estimated $33.5M and leaving 632,317 shares worth $15.2M. The position accounts for 0.06% of the portfolio, ranked #214.

Natixis first reported a position in PFE in Q2 2013 and has held it in 50 quarters since. The position peaked at $258M in Q2 2019. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Natixis held 632,317 shares of Pfizer worth $15.2M as of Q2 2026.
Natixis sold 1,279,917 Pfizer shares in Q2 2026, an estimated $33.5M.
Pfizer made up 0.06% of Natixis's portfolio in Q2 2026, its #214 holding.
Natixis first reported a position in Pfizer in Q2 2013 and has held it in 50 quarters since.
Natixis's Pfizer position peaked at $258M in Q2 2019.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.